| Literature DB >> 33003544 |
Hélène De Cannière1,2, Christophe J P Smeets1,2,3, Melanie Schoutteten1,2, Carolina Varon4,5, John F Morales Tellez4, Chris Van Hoof4,6, Sabine Van Huffel4, Willemijn Groenendaal3, Pieter Vandervoort1,2,7.
Abstract
Cardiac rehabilitation (CR) is a highly recommended secondary prevention measure for patients with diagnosed cardiovascular disease. Unfortunately, participation rates are low due to enrollment and adherence issues. As such, new CR delivery strategies are of interest, as to improve overall CR delivery. The goal of the study was to obtain a better understanding of the short-term progression of functional capacity throughout multidisciplinary CR, measured as the change in walking distance between baseline six-minute walking test (6MWT) and four consecutive follow-up tests. One-hundred-and-twenty-nine patients diagnosed with cardiovascular disease participated in the study, of which 89 patients who completed the whole study protocol were included in the statistical analysis. A one-way repeated measures ANOVA was conducted to determine whether there was a significant change in mean 6MWT distance (6MWD) throughout CR. A three-way-mixed ANOVA was performed to determine the influence of categorical variables on the progression in 6MWD between groups. Significant differences in mean 6MWD between consecutive measurements were observed. Two subgroups were identified based on the change in distance between baseline and end-of-study. Patients who increased most showed a linear progression. In the other group progression leveled off halfway through rehabilitation. Moreover, the improvement during the initial phase of CR seemed to be indicative for overall progression. The current study adds to the understanding of the short-term progression in exercise capacity of patients diagnosed with cardiovascular disease throughout a CR program. The results are not only of interest for CR in general, but could be particularly relevant in the setting of home-based CR.Entities:
Keywords: 6MWT; cardiac rehabilitation; cardiovascular disease; functional capacity
Year: 2020 PMID: 33003544 PMCID: PMC7601310 DOI: 10.3390/jcm9103160
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure A1Study population flow chart.
Baseline characteristics.
| Variable | Total Population |
|---|---|
|
| |
| Male | 92 (71.3%) |
| Age, years | 63 (11) |
| Height, m | 1.72 (1.70–1.74) |
| BMI, kg/m2 | 27.2 (5.0) |
| Active smoker | 28 (22%) |
| Past smoker | 47 (37%) |
|
| 45 (42–47) |
|
| 50 (47–53) |
|
| 26 (20%) |
| CRT-D | 15 (58%) |
| CRT-P | 11 (42%) |
|
| |
| MI, % | 32 (24.8%) |
| 38 (29.5%) | |
| CABG, % | 17 (13.2%) |
| PCI, % | 15 (11.6%) |
| Other, % | 27 (20.9%) |
|
| |
| Atrial fibrillation | 33 (25.6%) |
| Hypertension | 60 (46.5%) |
| Dyslipidemia | 53 (41.1%) |
| Diabetes | 21 (16.3%) |
|
| |
| Class I | 36 (27.9%) |
| Class II | 60 (46.5%) |
| Class III | 33 (25.6%) |
|
| |
| ACE inhibitor | 67 (51.9%) |
| Beta-blocker | 97 (75.2%) |
| Diuretics | 66 (51.2%) |
| Statins | 93 (72%) |
| Calcium-channel blockers | 10 (8%) |
| Anticoagulants | 42(32%) |
|
| |
| Peak VO2, mL/kg/min | 16.21 (5.33) |
| Percent predicted peak VO2, % | 58 (19) |
| Peak power, watts | 109 (102–115) |
| Respiratory exchange ratio | 1.09 (1.08) |
|
| |
| Distance, m | 468 (104) |
| Rest HR, bpm | 68 (65–70) |
| Rest blood pressure, mmHg | 127/75 (19/11) |
LV, left ventricular; CRT, cardiac resynchronization therapy; CRT-P, cardiac resynchronization therapy pacemaker; CRT-D, cardiac resynchronization therapy defibrillator. NYHA, New York Heart Association; ACE, angiotensin converting enzyme; CPET, cardiopulmonary exercise testing; 6MWT, six-minute-walking test; HR, heart rate. The information (except for the information obtained during the 6MWT) was collected from the electronic medical record. Information for only 101 CPET measurements were available.
Specifying “Other” reasons for referral.
| Reason for Referral, Others | ( |
|---|---|
| Non-ischemic cardiomyopathy | 9 (7%) |
| Low fitness level | 7 (5%) |
| Valve disease | 5 (4%) |
| Following CRT implantation | 6 (4%) |
Baseline characteristics for patients who completed all five 6MWTs (Complete) and patients who failed to finish the study protocol (Non-complete).
| Variable | Complete | Non-Complete | |
|---|---|---|---|
|
| |||
| Male | 65 (73%) | 27 (68%) | 0.534 |
| Age, yrs | 63 (10) | 62 (14) | 0.398 |
| Height, m | 1.72 (1.70–1.74) | 1.71 (1.67–1.74) | 0.498 |
| BMI, kg/m2 | 26.7 (4.1) | 28.4 (6.3) | 0.072 |
| Active smoker | 18 (20%) | 10 (25%) | 0.495 |
| Past smoker | 34 (38%) | 13 (33%) | 0.692 |
|
| 45 (43–49) | 42 (38–46) | 0.123 |
|
| 50 (47–53) | NA | |
|
| 17 (19%) | 9 (23%) | 0.627 |
| CRT-D | 10 (59%) | 5 (50%) | |
| CRT-P | 7 (41%) | 4 (50%) | |
|
| |||
| MI, % | 23 (26%) | 9 (23%) | 0.826 |
| 21 (24%) | 17 (43%) | 0.037 * | |
| CABG, % | 14 (16%) | 3 (8%) | 0.266 |
| PCI, % | 11 (12%) | 4 (10%) | 0.776 |
| Other, % | 20 (22%) | 7 (16%) | |
|
| |||
| Atrial fibrillation | 22 (25%) | 11 (28%) | 0.828 |
| Hypertension | 38 (43%) | 22 (55%) | 0.084 |
| Dyslipidemia | 39 (44%) | 14 (35%) | 0.440 |
| Diabetes | 12 (14%) | 9 (23%) | 0.208 |
|
| 0.222 | ||
| Class I | 26 (29%) | 10 (25%) | |
| Class II | 44 (50%) | 16 (40%) | |
| Class III | 19 (21%) | 14 (35%) | |
|
| |||
| ACE inhibitor | 50 (56.2%) | 17 (43%) | 0.184 |
| Beta-blocker | 63 (71%) | 34 (85%) | 0.122 |
| Diuretics | 39 (43%) | 27 (68%) | 0.014 * |
| Statins | 64 (71%) | 29 (73%) | 0.999 |
| Calcium-channel blockers | 9 (10%) | 1 (3%) | 0.172 |
| Anticoagulants | 28 (32%) | 14 (35%) | 0.690 |
|
| |||
| Peak VO2, mL/kg/min | 17.00 (5.09) | 14.06 (5.46) | 0.013 * |
| Percent predicted peak VO2, % | 60 (20) | 52 (18) | 0.373 |
| Peak power, watts | 114 (106–122) | 96 (84–108) | 0.014 * |
| Respiratory exchange ratio | 1.10 (0.10) | 1.05 (0.11) | 0.061 |
|
| |||
| Distance, m | 484 (96) | 431 (110) | 0.006 * |
| Rest HR, bpm | 68 (65–71) | 67 (63–71) | 0.543 |
| Rest blood pressure, mmHg | 127/76 (19/10) | 124/73 (18/13) | 0.320/0.006 * |
* p < 0.05.
Output paired sample t-test analyzing the difference in Short Form-36 (SF-36) scores between baseline and end-of-study.
| SF-36 Scores (Baseline—End-of-Study) | Mean (SD) | 95% CI | t-Value | Effect Size | |
|---|---|---|---|---|---|
| Physical Functioning | −14.09 (19.22) | −18.58 to −9.61 | −6.26 | ≤0.001 | −0.73 |
| Role Physical | −27.41 (46.99) | −38.22 to −16.60 | −5.05 | ≤0.001 | −0.58 |
| Role Emotional | −14.02 (42.71) | −25.35 to −2.69 | −2.48 | 0.016 | −0.33 |
| Vitality | −13.22 (17.85) | −17.30 to −9.13 | −6.45 | ≤0.001 | −0.74 |
| Mental Health | −9.20 (15.44) | −12.73 to −5.67 | −5.20 | ≤0.001 | −0.60 |
| Social Functioning | −20.31 (21.67) | −26.61 to −14.02 | −6.50 | ≤0.001 | −0.94 |
| Bodily Pain | −10.44 (24.47) | −17.39 to −3.49 | −3.02 | 0.004 | −0.43 |
| General Health | −2.61 (17.72) | −8.89 to 3.67 | −0.85 | 0.404 | −0.15 |
Output 6MWT at five different time points during rehabilitation.
| Baseline | 1st Follow-Up | 2nd Follow-Up | 3rd Follow-Up | End-of-Study | |
|---|---|---|---|---|---|
| Distance, m | 484 (96) | 533 (100) | 564 (100) | 570 (103) | 585 (104) |
| HR start 6MWT | 66 (57–80) | 67 (57–73) | 65 (58–72) | 64 (55–70) | 62 (55–72) |
| HR end 6MWT | 85 (73–94) | 86 (77–96) | 85 (77–103) | 89 (80–99) | 89 (79–104) |
6MWT, six-minute-walking test. Values are expressed as mean (standard deviation) or as median (interquartile range).
Figure 1Means and standard deviations of six-minute walking distance (6MWD) for each measurement session throughout the rehabilitation program. * p < 0.05.
Figure 2Means and standard deviations of six-minute walking distance (6MWD) walked during rehabilitation for subgroups based on the increase in distance throughout rehabilitation. * p < 0.05.